PARPi Resistant Biomarker Discovery Service

Poly (ADP-ribose) polymerase inhibitors (PARPis) have transformed cancer therapy, particularly for patients with homologous recombination deficiencies, such as those with BRCA1 and BRCA2 mutations. Alfa Cytology offers comprehensive PARPi resistant biomarker discovery services for our clients.

Introduction to PARPi Resistant Biomarker

While PARPis effectively induce cell death in these specific contexts, the emergence of resistance remains a significant clinical challenge. Understanding the mechanisms underlying PARPi resistance is crucial for optimizing treatment strategies and ensuring the efficacy of these therapies. Biomarkers associated with PARPi resistance provide essential insights into the underlying genetic and molecular mechanisms that allow cancer cells to evade the effects of these inhibitors. Research has identified various genetic alterations that contribute to resistance, including mutations in the EGFR, PTEN, and RB1 genes.

Fig. 1 Prediction of drug combination with PARPis. (Dong Q., et al. 2021)

Our Services

Alfa Cytology provides comprehensive services for discovering biomarkers associated with PARPi resistance. Our offerings include both blood-based and tissue biomarker discovery, utilizing advanced methodologies to deliver precise and actionable insights.

Blood-based Biomarker Discovery

Our blood-based biomarker discovery service focuses on identifying circulating tumor DNA (ctDNA) and other relevant biomarkers in blood samples. This minimally invasive approach allows for:

Real-time Monitoring
Early Detection of Resistance
Comprehensive Profiling

Tissue Biomarker Discovery

In addition to blood-based analyses, our tissue biomarker discovery service provides in-depth characterization of tumor biopsies. This service includes:

Genomic and Transcriptomic Analysis
Pathway Analysis
Histopathological Evaluation

Customizable Discovery Solutions

Recognizing the diverse needs of our clients, Alfa Cytology offers customizable biomarker discovery solutions. Our services can be tailored to focus on specific cancer types or therapeutic combinations, allowing researchers to address unique research questions. We collaborate closely with clients to align our discovery efforts with their objectives, providing expert guidance throughout the process.

Type of Technology

Flow Cytometry
ELISA, WB, IHC, IHF

qPCR, FISH
LC-MS/MS, NMR

MRI, PET
More

To learn more about our PARPi responsive biomarker discovery services or to discuss your specific research needs, please reach out to our expert team at Alfa Cytology. We are committed to advancing cancer research and improving patient outcomes through innovative biomarker discovery.

Reference

Dong Q., Liu M., and et al. Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. Comput Struct Biotechnol J. 2021, 19: 4435-4446.

For research use only. Not intended for any clinical use.